Drug Profile
Research programme: nanoparticle therapeutics - Cristal Therapeutics
Alternative Names: CPC 879; CriPec Actively Targeted Nanoparticles - Cristal Therapeutics; CriPec ATN - Cristal Therapeutics; CriPec oligonucleotides - Cristal Therapeutics; CriPec® DUO; CriPec® DUO - Cristal Therapeutics; CriPec® peptides - Cristal Therapeutics; Exenatide nanoparticle - Cristal Therapeutics; Leuprolide nanoparticle - Cristal Therapeutics; Octreotide nanoparticle - Cristal TherapeuticsLatest Information Update: 02 Apr 2020
Price :
$50
*
At a glance
- Originator Cristal Therapeutics
- Class Antineoplastics; Fluorinated steroids; Glucocorticoids; Peptides; Pregnadienetriols
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 02 Apr 2020 Discontinued for Solid tumours in Netherlands (IV)
- 08 Nov 2018 Cristal Therapeutics plans preclinical studies of CPC 879 for Cancer in Q4-2018 (Cristal Therapeutics pipeline, November 2018)
- 27 Jan 2016 Cristal Therapeutics has patent protection for drug delivery systems prepared using CriPec Technology (Cristal Therapeutics website, January 2016)